Fakhri Hassouneh, Nelson Lopez-Sejas, Carmen Campos, Beatriz Sanchez-Correa, Raquel Tarazona, Rafael Solana, Alejandra Pera
Abstract
Immunosenescence is a progressive deterioration of the immune system with aging. It affects both innate and adaptive immunity limiting the response to pathogens and to vaccines. As chronic cytomegalovirus (CMV) infection is probably one of the major driving forces of immunosenescence, and its persistent infection results in functional and phenotypic changes to the T-cell repertoire, the aim of this study was to analyze the effect of CMV-seropositivity and aging on the expression of CD300a and CD161 inhibitory receptors, along with the expression of CD57 marker on CD4(+), CD8(+), CD8(+)CD56(+) (NKT-Like) and CD4(-)CD8(-) (DN) T-cell subsets. Our results showed that, regardless of the T-cell subset, CD57(-)CD161(-)CD300a(+) T-cells expand with age in CMV-seropositive individuals, whereas CD57(-)CD161(+)CD300a(+) T-cells decrease. Similarly, CD57(+)CD161(-)CD300a(+) T-cells expand with age in CMV-seropositive individuals in all subsets except in DN cells and CD57(-)CD161(+)CD300a(-) T-cells decrease in all T-cell subsets except in CD4(+) T-cells. Besides, in young individuals, CMV latent infection associates with the expansion of CD57(+)CD161(-)CD300a(+)CD4(+), CD57(-)CD161(-)CD300a(+)CD4(+), CD57(+)CD161(-)CD300a(+)CD8(+), CD57(-)CD161(-)CD300a(+)CD8(+), CD57(+)CD161(-)CD300a(+)NKT-like, and CD57(+)CD161(-)CD300a(+)DN T-cells. Moreover, in young individuals, CD161 expression on T-cells is not affected by CMV infection. Changes of CD161 expression were only associated with age in the context of CMV latent infection. Besides, CD300a(+)CD57(+)CD161(+) and CD300a(-)CD57(+)CD161(+) phenotypes were not found in any of the T-cell subsets studied except in the DN subpopulation, indicating that in the majority of T-cells, CD161 and CD57 do not co-express. Thus, our results show that CMV latent infection impact on the immune system depends on the age of the individual, highlighting the importance of including CMV serology in any study regarding immunosenescence.
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2017.
All research outputs
#14,393,794
of 25,382,440 outputs
Outputs from Frontiers in immunology
#11,654
of 31,531 outputs
Outputs of similar age
#159,160
of 331,648 outputs
Outputs of similar age from Frontiers in immunology
#186
of 391 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 42nd percentile – i.e., 42% of other outputs scored the same or lower than it.
So far Altmetric has tracked 31,531 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,648 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 391 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
